FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey

 An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. 

Eli Lilly and Co plans to invest an additional $450 million to expand capacity of a plant in North Carolina, the U.S. drugmaker said on Tuesday, as it races to boost production ahead of a decision on its promising obesity treatment.

The company has been struggling to meet strong demand for its incretin products, which include its blockbuster diabetes drug Trulicity and recently launched Mounjaro. Last month, the U.S. Food and Drug Administration added both to its list of drugs facing shortages.